[go: up one dir, main page]

WO2013048355A2 - Composition à base d'herbes pour traiter la maladie de l'hépatite c et procédé d'utilisation de cette composition à base d'herbes - Google Patents

Composition à base d'herbes pour traiter la maladie de l'hépatite c et procédé d'utilisation de cette composition à base d'herbes Download PDF

Info

Publication number
WO2013048355A2
WO2013048355A2 PCT/TR2012/000118 TR2012000118W WO2013048355A2 WO 2013048355 A2 WO2013048355 A2 WO 2013048355A2 TR 2012000118 W TR2012000118 W TR 2012000118W WO 2013048355 A2 WO2013048355 A2 WO 2013048355A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
seed
disease
herbal composition
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2012/000118
Other languages
English (en)
Other versions
WO2013048355A3 (fr
Inventor
Vedat TATAROGLU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2013048355A2 publication Critical patent/WO2013048355A2/fr
Publication of WO2013048355A3 publication Critical patent/WO2013048355A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288—Taraxacum (dandelion)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger

Definitions

  • This invention is related to, a herbal composition for treating hepatitis C disease and the method of usage of this herbal composition in treating hepatitis C disease.
  • Hepatitis C is a virus from the flavivridae virus " group. Hepatitis C is the most frequent blood borne infectious disease typ. It leads to Hepatitis C disease also known as HCV. The disease starts suddenly most of the time and spreads in very short period of time. The mild or medium syndromes usually cannot be perceived by the person infected with this disease. At this point a blood graphic that shows a mild increase in the liver enzymes can be seen. It has been proved by scientific studies that the disease in 85% of people who are going through the acute phase usually develop the disease into chronic hepatitis and more importantly 20% of the people diagnosed with this disease develop epidemic liver inflammation also named as cirrhosis.
  • liver failure a tissue that is hard, non functional and useless
  • the disease also leads to problems such as nausea, malaise, fatigue, loss of appetite, headache, fever, and stomach pains.
  • the aim of this invention is to produce an herbal composition which is totally natural and which does not have any of the side effects mentioned above and which shall be used in the treatment of hepatitis C disease; and to lay out the methods of usage of this herbal composition in treating hepatitis C.
  • Another purpose of the invention is to establish a herbal composition that will aid in overcoming the problems that hepatitis C disease causes.
  • the herbal composition in order to reach the aim of this invention, comprises thistle seed, artichoke, licorice, turmeric, ginseng, carob, nettle seed, nigella, ginger, taraxacum and honey.
  • one or more of the following ingredients of celery seed, linseed, walnuts, black grapes, harmal, daisy, black radish seed, strawberry, carnation, cinnamon and thyme can be added into the composition for overcoming complaints such as malaise, fatigue, loss of appetite, fever, headache and stomach aches that are caused by hepatitis C disease.
  • the herbal composition of this present invention comprises, thistle seed, artichoke, licorice, turmeric, ginseng, carob, nettle seed, nigella, ginger, taraxacum and honey.
  • the herbal composition subject to this invention can be used to overcome complaints caused by hepatitis C disease such as nausea, malaise, fatigue, loss of appetite, fever, headache and stomach pains and one or more of the ingredients of celery seed, linseed, walnut, black grapes, harmal, daisy, black radish seed, strawberry, carnation, cinnamon and thyme can be added to the composition.
  • the composition is formed by gathering an equal amount of thistle seed artichoke, licorice, turmeric, ginseng, carob, nettle seed, nigella, ginger and taraxacum, then grinding these herbs and adding and mixing this mixture of grinded herbs into honey, 10 times the weight of this herbal mixture.
  • the thistle seed inside the composition comprises a high amount of silymarin, made up of silybin, silydianin and silychristin.
  • Silymarin protects against the harmful effects of the free radicals of liver with its antioxidant feature. It has been proved by clinical studies conducted that Silymarin is a strong preventer of many leukotrienes that are harmful to the liver. It has been proved that Silymarin has a positive effect on many liver diseases such as cirrhosis, chronic hepatitis, and the oil infiltration of liver.
  • the artichoke inside the composition contains, hydroxicinnamic acid, sesquiterpenelacton and its derivations, flavonoides, tannin, inulin, and adhesive substances. These substances enable rapid recovery and strengthening of the liver.
  • the turmeric inside the composition contains, a high amount of curcumine and dicinnamoylmethane. These substances are beneficial in getting rid of toxic materials that have accumulated in the body and in overcoming liver problems.
  • the ginseng (Korean ginseng) inside the composition stimulates the protein, nucleic acid synthesis, carbohydrate and fat metabolism of the body via the glycosides named panaxoside, and enables the burning of the toxic substances obtained externally or produced by the body itself and the enables the rapid excretion of these toxic materials from the body and thus, helps to regenerate the liver cells.
  • the carob inside the composition contains high amounts of saccharose, glucose, cellulose, sodium and potassium. It has a high healing effect on the liver and the lungs.
  • the nettle seed inside the composition contains, histamine, chlorophyll and acetylcholine. It helps to get rid of extra edema and infection inside the body and is used in liver complaints.
  • the Nigella inside the composition contains thymoquinone, dithymoquinone, thymohydroquinone and thymol oils. The Nigella helps in speeding up the cell regeneration process.
  • the ginger inside the composition contains ethereal oils (sesquiterpenes, sesquiterpene-alcohols and monoterpenes) and arylalkanes. These oils are considerably effective in getting rid of tissue infections.
  • the taraxacum inside the composition contains potassium, torexacine, retinol, levulin and inulin and thus plays a role in increasing liver secretion.
  • As the licorice inside the composition contains glycyrrhizin, flavon, saponyn, and coumarin substances it is the most effective substance to fight against harmful bacteria with its antibacterial, antifungal effect. This is helpful in stopping the disease progression and healing the disease with its antiviral effect in the treatment of chronic hepatitis A, Hepatitis C and cirrhosis.
  • mixture is a homogeneous mixture. Following this, this mixture taken from the grinder is added into honey which is 10 times the weight of the said mixture and the composition is then obtained.
  • the composition shall be taken 3 times a day 1.5 hours before each meal.
  • the dosage of the composition shall be calculated by taking the body weight of the person that will use this composition as basis.
  • the dosage should be taken as 0. lgr per weight daily.
  • a daily consumption of a person who is 90 kilograms shall be arranged as 9gr and this 9gr should also be divided in to 3 and taken 3 times a day as 3 grams each time.
  • one or more of the ingredients of celery seed, linseed, walnut, black grapes, harmal, daisy, black radish seed, strawberry, carnation, cinnamon and thyme can be added to the composition in order to overcome complaints caused by hepatitis C disease such as nausea, malaise, fatigue, loss of appetite, fever, headache and stomach pains.
  • the preparation amounts of the composition and the application or usage shall also be carried out as mentioned above.
  • the celery seed inside the composition provides a good preventive effect against liver diseases and especially plays an important role in getting rid of liver bloating as it contains A,B and C vitamins, calcium, iron, potassium and lime.
  • the linseed inside the composition is effective in healing stomach and belly aches as it contains mucilage and linamarin.
  • as the walnut inside the composition comprises A, Bl, B6 vitamins, sodium chlorine, magnesium, potassium, and zinc it provides high energy and is good for overcoming fatigue and malaise.
  • the composition contains Harman seed, which comprises harmin, harmol, peganin and harmalin and these are good in curing stomach and belly aches.
  • composition As the daisy inside the composition according to another embodiment of the invention comprises bisababol, bisabalol oxide, amino acids, chamuzelene, cadinen, capryl acid, cholin, fernesan, geroniol, pytosterine and carotene it is quite protective against cancer and it prevents belly aches and the formation of infections.
  • the black radish seed (horseradish) inside the composition according to another alternative embodiment of the invention contains glycoraphania which stimulates the liver cells and helps clean out infections.
  • the strawberry inside the composition according to another embodiment of the invention contains ethyl acetate, ethyl hexanoate, ethyl ochtanoate, methylhexanoate 5-hidroxy methyl 2 furfural which are protective against cancer, which provide strength to the body, which are beneficial in healing liver diseases and helping to get rid of toxic substances that have accumulated in the body.
  • the cinnamon inside the composition according to another embodiment of the invention contains cinnamic aldehyde, hydrocinnamic aldehyde, and eugenol which have an appetizing effect.
  • the carnation inside the composition according to another embodiment of the invention contains, flavones, tannins, and triterpenes which are helpful in relieving pain, which have a disinfectant effect and which are beneficial in getting rid of infectious weeping.
  • the thyme inside the composition according to the alternative embodiment of the invention contains phenolic, flavonide compounds, ursolic, oleanolic acid and triterpenic substances which are germicidal, anti inflammatory, and which act as appetizing agents.
  • the composition has been tested on a 48 year old male with hepatitis C disease and the patient has been monitored to control the progression of the disease. Before the usage of the composition it has been recorded that the person was positive for Hcv-Rna and Anti-Hcv values, and that the Bottom, top and Ggt values were 65, 117 and 108. Following the regular usage of the composition, the measured values have shown progress and during the final examination it was recorded that the Bottom, top and Ggt values were 20,25 and 13, and it was seen that the Hcv-Rna and Anti-Hcv values had turned into negative and that the disease was totally cured.
  • composition subject to this invention effective results in treating hepatitis C have been obtained.
  • Both cleaning hepatitis C virus from the blood via the usage of the herbal products inside the composition, and preventing liver infection, and also cleaning the already formed infection in the liver to ensure that the liver returns back to its healthy functioning state is achieved by the usage of the composition.
  • the substances inside the herbs comprising the composition used to dry up the infection and clean out the liver might have trans-effects when used together or might neutralize each other when used together, the usage of licorice according to this invention in the composition prevents this said trans-effect or neutralization possibility.
  • the application doses and usage types have been determined in order to provide the maximum positive effect.
  • both a natural composition without any side effects has been produced and an effective result has been obtained with the application method of this said composition in treating hepatitis C disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention concerne une composition à base d'herbes pour traiter la maladie de l'hépatite C et le procédé d'utilisation de cette composition à base d'herbes dans le traitement de la maladie de l'hépatite C. La composition à base d'herbes pour atteindre le but de l'invention comprend des graines de chardon, de l'artichaut, de la réglisse, du curcuma, du ginseng, de la caroube, des graines d'orties, de la nigelle, du gingembre, du taraxacum et du miel.
PCT/TR2012/000118 2011-08-01 2012-08-01 Composition à base d'herbes pour traiter la maladie de l'hépatite c et procédé d'utilisation de cette composition à base d'herbes Ceased WO2013048355A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2011/07537A TR201107537A2 (tr) 2011-08-01 2011-08-01 Hepatit c hastalığınınn iyileştirilmesi için bitkisel bir kompozisyon ve bu bitkisel kompozisyonun kullanım yöntemi.
TR2011/07537 2011-08-01

Publications (2)

Publication Number Publication Date
WO2013048355A2 true WO2013048355A2 (fr) 2013-04-04
WO2013048355A3 WO2013048355A3 (fr) 2013-05-30

Family

ID=47459071

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2012/000118 Ceased WO2013048355A2 (fr) 2011-08-01 2012-08-01 Composition à base d'herbes pour traiter la maladie de l'hépatite c et procédé d'utilisation de cette composition à base d'herbes

Country Status (2)

Country Link
TR (1) TR201107537A2 (fr)
WO (1) WO2013048355A2 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014188325A1 (fr) * 2013-05-20 2014-11-27 Indus Biotech Private Limited Procede pour gerer une fibrose hepatique, le virus de l'hepatite c et un etat associe
US9402834B2 (en) 2014-10-21 2016-08-02 Ions Pharmaceutical S.À R.L. Human therapeutic agents
WO2017129198A1 (fr) * 2016-01-26 2017-08-03 أمل صدفي سعد على، Composition naturelle qui renforce le système immunitaire par activation des glandes pour résister aux virus, bactéries et autres microbes
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
WO2018053123A1 (fr) * 2016-09-14 2018-03-22 Phoenix Biotechnology, Inc. Méthodes et compositions de traitement d'infections virales
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
IT202200015906A1 (it) * 2022-07-27 2024-01-27 Carepharm S R L Composizione erboristica edibile contenente silicio e procedimento per ottenerla
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039179A1 (fr) 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841174B2 (en) * 2000-09-20 2005-01-11 Zeyad Technologies Llc Herbal compositions and treatment methods
US6455078B1 (en) * 2000-10-18 2002-09-24 Tzu-Sheng Wu Medicinal herbal composition for treating liver diseases and HIV

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039179A1 (fr) 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions de traitement de l'hépatite c et procédés d'utilisation des compositions de traitement de l'hépatite c

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775826B2 (en) 2013-05-20 2017-10-03 Indus Biotech Private Limited Method of managing Hepatic fibrosis, Hepatitis C virus and associated condition
WO2014188325A1 (fr) * 2013-05-20 2014-11-27 Indus Biotech Private Limited Procede pour gerer une fibrose hepatique, le virus de l'hepatite c et un etat associe
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9402834B2 (en) 2014-10-21 2016-08-02 Ions Pharmaceutical S.À R.L. Human therapeutic agents
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
WO2017129198A1 (fr) * 2016-01-26 2017-08-03 أمل صدفي سعد على، Composition naturelle qui renforce le système immunitaire par activation des glandes pour résister aux virus, bactéries et autres microbes
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11007239B2 (en) 2016-09-14 2021-05-18 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
CN111093672A (zh) * 2016-09-14 2020-05-01 菲尼克斯生物技术公司 用于治疗病毒感染的方法和组合物
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
WO2018053123A1 (fr) * 2016-09-14 2018-03-22 Phoenix Biotechnology, Inc. Méthodes et compositions de traitement d'infections virales
US10874704B2 (en) 2016-09-14 2020-12-29 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10980852B2 (en) 2016-09-14 2021-04-20 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US11013776B2 (en) 2016-09-14 2021-05-25 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US11123387B2 (en) 2016-09-14 2021-09-21 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US11324789B2 (en) 2016-09-14 2022-05-10 Phoenix Biotechnology, Inc. Method and compositions for treating equine encephalitis
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
IT202200015906A1 (it) * 2022-07-27 2024-01-27 Carepharm S R L Composizione erboristica edibile contenente silicio e procedimento per ottenerla
EP4311540A1 (fr) * 2022-07-27 2024-01-31 Carepharm S.r.l. Composition comestible a base d'herbes contenant du dioxide de silicium et procede d'obtention

Also Published As

Publication number Publication date
TR201107537A2 (tr) 2012-01-23
WO2013048355A3 (fr) 2013-05-30

Similar Documents

Publication Publication Date Title
WO2013048355A2 (fr) Composition à base d'herbes pour traiter la maladie de l'hépatite c et procédé d'utilisation de cette composition à base d'herbes
US20130337090A1 (en) Plant extracts for treating burns and chronic wounds
CN101919944B (zh) 一种治疗急性脑梗塞的中药组合物及其制备方 法和应用
CN102872241A (zh) 一种用于治疗炎症性皮肤病的中药组合物及其制剂
CN103386022A (zh) 一种治疗结核性胸膜炎的中药组合物
CN102755573A (zh) 一种治疗灰指甲的外用中药
CN1189197C (zh) 一种具有消炎止血止痛活血生肌的中药
CN105999219A (zh) 用于引流排毒的药物
CN102988564A (zh) 一种治疗日晒疮的中药组合物
CN102743707B (zh) 治疗急性腰扭伤药丸
CN101703657B (zh) 一种治疗刺瘊的外用制剂
CN101181551B (zh) 治疗痔疮的外用软膏
CN110559306A (zh) 野蔷薇苷在制备治疗或预防辐射损伤的药物中的应用
CN104162119A (zh) 一种治疗小儿外感咳嗽的中药
CN1332697C (zh) 一种治疗结核病的中药
CN108236674A (zh) 类风湿康复贴的制备方法
RU2442595C2 (ru) Фитокомплекс для лечения онкологических заболеваний и способ лечения заболеваний желудочно-кишечного тракта с его применением
CN102949499A (zh) 一种用于烫伤的中药组合物及制备方法
CN101623346A (zh) 一种治疗急性腰损伤的中药组合物
CN1177592C (zh) 红芪提取物总皂甙在制备治疗心肌炎药物中的应用
CN105920175A (zh) 一种治疗皮肤湿疹瘙痒的药物组合物及其制备方法
CN104740565A (zh) 一种治疗冻伤的中药组合物
Bałan et al. Review paper Immunotropic activity of Echinacea. Part II. Experimental and clinical data
CN102861111B (zh) 一种预防和治疗甲肝、乙肝、丙肝的药物
CN104644989A (zh) 一种治疗风湿的中药配方

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12808524

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06/05/2014)

122 Ep: pct application non-entry in european phase

Ref document number: 12808524

Country of ref document: EP

Kind code of ref document: A2